HLA-Compass für sichere Immuntherapien

Alithea Biotechnology's cloud-based HLA-Compass platform is designed to accelerate the discovery and validation of safe immunotherapies by providing access to a large quantitative database of Human Leukocyte Antigen (HLA) presented peptides. The platform's features include an extensive dataset of over 1.56 million peptides and 10,000 cancer-specific epitopes derived from high-quality samples, broad HLA type coverage, and an AI-driven binding prediction tool.